Research Topics
| A NoySummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Update on HIV lymphomaAriela Noy
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10064, USA
Curr Oncol Rep 9:384-90. 2007..Overall, the outcome for non-Hodgkin's lymphoma and Hodgkin's lymphoma in the setting of HIV continues to improve as insights into the pathophysiology and treatment advance...- The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)A Noy
Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Ann Oncol 20:508-12. 2009.... - Update in HIV-associated lymphomaAriela Noy
Division of Hematology, Memorial Sloan Kettering Cancer, Weill Medical College of Cornell University, New York, New York 10021, USA
Curr Opin Oncol 16:450-4. 2004..Infection with human immunodeficiency virus (HIV) is associated with an increased risk of non-Hodgkin lymphoma and Hodgkin disease. This review summarizes developments within the past 18 months... - Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study TeamAriela Noy
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 23:990-8. 2005..We report a 24-week, randomized, double-blinded, placebo-controlled phase III trial with the phase II dose, 5 mg intranasally every other day... - Controversies in the treatment of Burkitt lymphoma in AIDSAriela Noy
Hematology Division, Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Curr Opin Oncol 22:443-8. 2010..Increasingly then, the risks of HIV associated cancers become paramount. Burkitt lymphoma is one of the cancer subtypes highly disproportionately affecting HIV infected patients... - Telomeres: the long and short of developing non-Hodgkin lymphomaAriela Noy
Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 15:7114-5. 2009..Telomeres are tandem sequences at chromosome ends that provide protection for the genetic coding material. Erosion of those ends leads to cell death. Does stabilization promote cancer?.. - Update in Kaposi sarcomaAriela Noy
Department of Lymphoma and Clinical Immunology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
Curr Opin Oncol 15:379-81. 2003..Knowledge of the pathophysiology of Kaposi sarcoma continues to expand and influence our therapeutic approaches. This review summarizes developments within the last 18 to 24 months... - Gastric mucosa-associated lymphoid tissue lymphoma detected by clonotypic polymerase chain reaction despite continuous pathologic remission induced by involved-field radiotherapyAriela Noy
Lymphoma Disease Management Team and Laboratroy of Molecular Hemato Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 23:3768-72. 2005..We have previously demonstrated long-term pathologic remission after involved-field radiotherapy therapy (IFRT). We determined molecular remission status by clonotypic polymerase chain reaction (PCR)... - Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocolA Noy
Department of Medicine Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Blood 97:1929-36. 2001..These data support the conclusions that nodular PR in CLL represents MRD and that clonotypic PCR detects MRD in CLL more frequently than flow cytometry or immunohistochemistry. (Blood. 2001;97:1929-1936).. - Update in HIV lymphomaAriela Noy
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Curr Opin Oncol 18:449-55. 2006..Lymphoma is the most common HIV-associated malignancy in these countries. This review summarizes progress from January 2005 to March 2006... - Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphomaPaul A Hamlin
Lymphoma and Hematology Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Box 350, 1275 York Ave, New York, NY, 10021
Blood 102:1989-96. 2003..This powerful prognostic instrument should be used to evaluate new treatment approaches and to compare results of different regimens... - R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacyJeffrey L Halaas
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Leuk Lymphoma 46:541-7. 2005..Whether adding rituximab and increasing dose intensity improves survival over either alone will require randomized studies... - Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experienceS M Edwards-Bennett
Lymphoma Disease Management Team and Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Ann Oncol 21:574-81. 2010..We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data... - Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphomaEunice S Wang
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021-6306, USA
Cancer 98:1196-205. 2003..In the post-HAART era, intensive chemotherapy such as CODOX-M/IVAC may be appropriate in all adult patients with BL, and especially those with poor prognostic factors, regardless of HIV status... - Spectrum of HIV lymphoma 2009Ayca Gucalp
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Curr Opin Hematol 17:362-7. 2010..Lymphomas comprise a large proportion of the malignancies that affect the HIV-infected population in developed countries. This review summarizes the recent progress made in HIV lymphoma research published in 2009 through January 2010... - Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphomaB J Cohen
Division of Hematology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Leuk Lymphoma 42:1015-22. 2001.... - Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantationDorothy Pan
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer J 8:371-6. 2002..DISCUSSION: Rituximab is effective and well-tolerated palliative treatment for aggressive non-Hodgkin's lymphomas that relapse after or is refractory to autologous stem cell transplantation... - Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classificationM J Matasar
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Ann Oncol 23:159-66. 2012..The impact of the WHO classification on the frequency of diagnostic discrepancy in lymphoma is unknown... - Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantationTrudy N Small
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Biol Blood Marrow Transplant 15:1538-42. 2009..5microg of PT induces an inadequate response. Prospective trials evaluating BOOSTRIX, containing 8microg/dose of PT (approved for adults in December 2008) are warranted in this vulnerable population undergoing transplantation... - Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphomaCraig H Moskowitz
Departments of Medicine, Radiology, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
J Clin Oncol 28:1896-903. 2010..Outside of a clinical trial, we recommend biopsy confirmation of an abnormal interim FDG-PET scan before changing therapy... - Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responsesNicole Lamanna
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 27:491-7. 2009..In that study, cyclophosphamide consolidation improved the frequency of complete response (CR) four-fold. Subsequently, rituximab was added to this regimen (F-->C-->R)... - High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imagingCraig H Moskowitz
Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Br J Haematol 148:890-7. 2010..61. Risk-adapted augmentation of salvage treatment in patients with HL is feasible and improves EFS in poorer-risk patients. Our data suggest that normalisation of FI pre-ASCT predicts outcome, and should be the goal of salvage treatment... - Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999Paul A Hamlin
Medicine Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Br J Haematol 130:691-9. 2005.... - Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomaTarun Kewalramani
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Blood 103:3684-8. 2004..25). RICE appears to induce very high CR rates in patients with relapsed and refractory DLBCL; however, further studies are necessary to determine whether this treatment regimen will improve outcomes after ASCT... - Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's diseaseCarol S Portlock
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
Br J Haematol 125:701-8. 2004..CD20(+) cHD is a poor prognostic factor for TTF and OS. All cHD cases should be immunophenotyped for CD20. A large prospective trial is needed to confirm these findings... - Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin diseaseDavid J Straus
Memorial Sloan Kettering Cancer Center, SR 441B Box 406, 1275 York Ave, New York, NY 10021, USA
Blood 104:3483-9. 2004..Although significant differences were not seen, it is possible that a benefit in outcome of less than 20% for CMT might be seen in a larger trial... - Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphomaHeiko Schoder
Memorial Sloan Kettering Cancer Center, Department of Radiology, Nuclear Medicine Service, Box 77, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 23:4643-51. 2005..18)Fluorodeoxyglucose positron emission tomography (FDG PET) is widely used for the staging of lymphoma. We investigated whether the intensity of tumor FDG uptake could differentiate between indolent and aggressive disease... - Developing a cancer-specific geriatric assessment: a feasibility studyArti Hurria
Department of Medicine, Psychiatry and Behavioral Sciences, and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 104:1998-2005. 2005.... - Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphomaC H Moskowitz
Lymphoma and Hematology Services, Department of Medicine, and Departments of Radiotherapy, Pathology, and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 17:3776-85. 1999.... - Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034Amy Chadburn
Weill Cornell Medical College, New York, NY 10065, USA
J Clin Oncol 27:5039-48. 2009..We sought to determine whether immunohistochemical analyses of biopsies from patients with DLBCL having HIV infection are similarly relevant for prognosis... - Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategyC S Portlock
Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10021, USA
Ann Oncol 19:254-8. 2008..pylori, hepatitis C and Borrelia serologies, Borrelia and Chlamydia fixed tissue PCR, Chlamydia peripheral blood mononuclear cell PCR and hydrogen breath test for small bowel bacterial overgrowth (SBBO) were obtained... - Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphomaOwen A O'Connor
Lymphoma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10032, USA
Br J Haematol 139:425-8. 2007..For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL... - CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patientsJ Teruya-Feldstein
Department of Pathology, Memorial Sloan Kettering Cancer Center, NY 10021, USA
Ann Oncol 15:1673-9. 2004.... - Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1 receptor inhibitor, in AIDS-Kaposi's sarcomaAriela Noy
AIDS 21:113-5. 2007 - Successful treatment of marginal zone lymphoma with splenectomy alone despite HIV infectionAntonette Withehead
AIDS 21:1655-6. 2007
Research Grants
- CLONOTYPIC PCR FOR MINIMAL RESIDUAL DISEASE IN LYMPHOMAAriela Noy; Fiscal Year: 2002..In addition, the extensive patient population facilitates the execution of a large number of clinical protocols in a timely manner. ..